C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

C-C chemokine receptor type 4 (CCR4) is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in the trafficking of dendritic cells.

The CCR4 pipeline market research report provides comprehensive information on the CCR4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, the latest news as well as press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Therapy Areas in the CCR4 Pipeline Products Market

The key therapy areas in the CCR4 pipeline products market are oncology, dermatology, ear nose throat disorders, gastrointestinal, ophthalmology, and respiratory.

CCR4 Pipeline Products Market Analysis by Therapy Areas

CCR4 Pipeline Products Market Analysis by Therapy Areas

For more therapy area insights, download a free report sample

Key Mechanisms of Action in the CCR4 Pipeline Products Market

The key mechanism of action in the CCR4 pipeline products market is C-C Chemokine Receptor Type 4 Antagonist.

Key Routes of Administration in the CCR4 Pipeline Products Market

The key routes of administration in the CCR4 pipeline products market are oral and intravenous.

CCR4 Pipeline Products Market Analysis by Routes of Administration

CCR4 Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the CCR4 Pipeline Products Market

The key molecule types in the CCR4 pipeline products market are small molecule, peptide, gene-modified cell therapy, monoclonal antibody, and recombinant protein.

CCR4 Pipeline Products Market Analysis by Molecule Types

CCR4 Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Major Companies in the CCR4 Pipeline Products Market

The major companies in the CCR4 pipeline products market are ChemoCentryx Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd, Lassogen Inc, RAPT Therapeutics Inc, and Tizona Therapeutics Inc.

CCR4 Pipeline Products Market Analysis by Companies

CCR4 Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

CCR4 Pipeline Products Market Report Overview

Key Therapy Areas Oncology, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Ophthalmology, and Respiratory
Key Mechanisms of Action C-C Chemokine Receptor Type 4 Antagonist
Key Routes of Administration Oral and Intravenous
Key Molecule Type Small Molecule, Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody, and Recombinant Protein.
Major Companies ChemoCentryx Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd, Lassogen Inc, RAPT Therapeutics Inc, and Tizona Therapeutics Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

ChemoCentryx Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Lassogen Inc
RAPT Therapeutics Inc
Tizona Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Overview

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Companies Involved in Therapeutics Development

ChemoCentryx Inc

CohBar Inc

Eight Plus One Pharmaceutical Co Ltd

Lassogen Inc

RAPT Therapeutics Inc

Tizona Therapeutics Inc

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Drug Profiles

BJY-809 – Drug Profile

Product Description

Mechanism Of Action

CB-5046 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CCX-6239 – Drug Profile

Product Description

Mechanism Of Action

History of Events

FLX-475 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas – Drug Profile

Product Description

Mechanism Of Action

History of Events

LAS-20X – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Target CCR4 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

RPT-193 – Drug Profile

Product Description

Mechanism Of Action

History of Events

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Dormant Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Discontinued Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Product Development Milestones

Featured News & Press Releases

May 23, 2022: RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis

Mar 28, 2022: RAPT Therapeutics announces biomarker data from phase 1b trial of RPT193 consistent with disease modification in atopic dermatitis

Oct 18, 2021: RAPT Therapeutics announces upcoming oral presentation of RPT193 phase 1b data at the 4th Inflammatory Skin Disease Summit

Sep 30, 2021: RAPT Therapeutics announces late-breaking oral presentation of positive results from phase 1b trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress

Sep 20, 2021: RAPT Therapeutics to present RPT193 phase 1b data at 30th European Academy of Dermatology and Venereology Congress

Jun 14, 2021: RAPT Therapeutics reports positive topline results from phase 1b trial of RPT193 monotherapy in atopic dermatitis

Jun 13, 2021: RAPT Therapeutics to report top line data from phase 1b trial of RPT193 in atopic dermatitis

Mar 22, 2021: Rapt Therapeutics completes enrollment in phase 1b trial of RPT193 in atopic dermatitis

Nov 16, 2020: RAPT Therapeutics reports positive initial data from ongoing phase 1/2 clinical trial of FLX475 in multiple cancer indications

Nov 15, 2020: RAPT Therapeutics to announce initial data from phase 1/2 clinical trial of FLX475 in multiple cancer indications

May 15, 2020: RAPT Therapeutics highlights early results for RPT193 at Society for Investigative Dermatology Meeting

Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193

Jul 08, 2019: RAPT Therapeutics announces the appointment of Emma Guttman-Yassky, M.D., Ph.D., a leading expert in the field of inflammatory skin diseases, to its scientific advisory board

May 13, 2019: FLX Bio highlights preclinical atopic dermatitis and asthma data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019

Nov 29, 2018: ChemoCentryx announces presentation on novel small molecule inhibitor CCX6239 at American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by ChemoCentryx Inc, 2022

Pipeline by CohBar Inc, 2022

Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2022

Pipeline by Lassogen Inc, 2022

Pipeline by RAPT Therapeutics Inc, 2022

Pipeline by Tizona Therapeutics Inc, 2022

Dormant Products, 2022

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.